Ameriprise
MJN

Ameriprise’s Mead Johnson Nutrition Company MJN Stock Holding History

Ameriprise’s Portfolio MJN Stock Details MJN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,900
Closed -$1.33M – 3854
2017
Q1 		$1.33M Buy
+14,900
New +$1.23M ﹤0.01% 2755

Other funds holding MJN

PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
FNBOO
First National Bank of Omaha Omaha, Nebraska $3.24B AUM 18.68% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return
WEC
Winslow Evans & Crocker Boston, Massachusetts $528M AUM 30.99% 1-Year Est. Return

Ameriprise's MJN Position: Q2 2017 in Review

Ameriprise sold out of Mead Johnson Nutrition Company (MJN) in Q2 2017, closing a stake of 210,486 shares — an estimated $18.8M sold.

Ameriprise first reported a position in MJN in Q2 2013 and held it in 16 quarters. The position peaked at $486M in Q2 2014. 7 funds tracked by Wall St. Rank hold MJN as of Q2 2017.

  • Ameriprise reported no remaining Mead Johnson Nutrition Company position as of Q2 2017 after selling out during the quarter.
  • Ameriprise sold 210,486 Mead Johnson Nutrition Company shares in Q2 2017, an estimated $18.8M.
  • Ameriprise first reported a position in Mead Johnson Nutrition Company in Q2 2013 and held it in 16 quarters.
  • Ameriprise's Mead Johnson Nutrition Company position peaked at $486M in Q2 2014.
  • 7 funds tracked by Wall St. Rank held Mead Johnson Nutrition Company as of Q2 2017.

Based on Ameriprise's 13F filing for Q2 2017, filed 10 Aug 2017.